New Triple-Therapy trial aims to shrink liver tumors for transplant
NCT ID NCT07059494
Summary
This study is testing whether a three-part treatment can help people with liver cancer become eligible for a liver transplant. It combines a targeted radiation treatment (Y-90) with two drugs (atezolizumab and bevacizumab) to try to shrink or control tumors. The goal is to either keep the cancer in check while patients wait for a transplant or shrink tumors enough so more patients can qualify for one.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Conditions
Explore the condition pages connected to this study.